http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Prediction of a subcooled boiling flow with advanced two-phase flow models
Yun, B.J.,Splawski, A.,Lo, S.,Song, C.H. North-Holland Pub. Co 2012 Nuclear engineering and design Vol.253 No.-
Prediction of bubble size which governs interfacial transfer terms between the two phases is of importance for an accurate prediction of the subcooled boiling flow. In the present work, a mechanistic bubbles size model, S<SUB>γ</SUB> was examined to enhance the prediction capability of subcooled boiling flows for the CFD (computational fluid dynamics) code. In addition to this, advanced subcooled boiling models such as new wall boiling and two-phase logarithmic wall function models were also applied for an improvement of energy partitioning and two-phase turbulence models, respectively. The benchmark calculation against the DEBORA subcooled boiling data confirms that the S<SUB>γ</SUB> bubble size model with the two advanced subcooled boiling models shows good prediction results and is applicable to the wide range of flow conditions that are expected in the nominal and postulated accidental conditions of a nuclear power plant.
Kang, Elise,Khalili, Ali,Splawski, Judy,Sferra, Thomas J.,Moses, Jonathan The Korean Society of Pediatric Gastroenterology 2018 Pediatric gastroenterology, hepatology & nutrition Vol.21 No.4
Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.
Elise Kang,Ali Khalili,Judy Splawski,Thomas J. Sferra,Jonathan Moses 대한소아소화기영양학회 2018 Pediatric gastroenterology, hepatology & nutrition Vol.21 No.4
Loss of response to anti-tumor necrosis factor (anti-TNF) agents in the treatment of inflammatory bowel disease (IBD) is a major consideration to maintain sustained response. Reversal of immunogenicity can re-establish response and increase the durability of these agents. Strategies to reverse immunogenicity include dose-intensification and/or the addition of an immunomodulator. However, there is a relative paucity of data on the efficacy of such interventions in pediatric IBD patients. Available reports have not strictly utilized homogenous mobility shift assay, which reports on anti-drug antibodies even in the presence of detectable drug, whereas prior studies have been confounded by the use of drug sensitive assays. We report four pediatric inflammatory bowel disease patients with successful reversal of immunogenicity on an anti-TNF agent using dose intensification and/or addition of an immunomodulator.